546 related articles for article (PubMed ID: 27031563)
1. Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.
Mohamed QA; Fletcher EC; Buckle M
BMJ Clin Evid; 2016 Mar; 2016():. PubMed ID: 27031563
[TBL] [Abstract][Full Text] [Related]
2. Age-related macular degeneration: anti-vascular endothelial growth factor treatment.
Arnold JJ
BMJ Clin Evid; 2016 Feb; 2016():. PubMed ID: 26909890
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Parravano M; Menchini F; Virgili G
Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and diabetic macular edema.
Lally DR; Shah CP; Heier JS
Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
[TBL] [Abstract][Full Text] [Related]
5. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
6. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.
Mehta H; Gillies MC; Fraser-Bell S
Clin Exp Ophthalmol; 2016 May; 44(4):335-9. PubMed ID: 27061760
[TBL] [Abstract][Full Text] [Related]
8. Current intravitreal pharmacologic therapies for diabetic macular edema.
Colucciello M
Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
[TBL] [Abstract][Full Text] [Related]
9. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
11. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
12. Management paradigms for diabetic macular edema.
Mitchell P; Wong TY;
Am J Ophthalmol; 2014 Mar; 157(3):505-13.e1-8. PubMed ID: 24269850
[TBL] [Abstract][Full Text] [Related]
13. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
Massa H; Nagar AM; Vergados A; Dadoukis P; Patra S; Panos GD
J Int Med Res; 2019 Jan; 47(1):31-43. PubMed ID: 30556449
[TBL] [Abstract][Full Text] [Related]
15. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
Avery RL; Gordon GM
JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
[TBL] [Abstract][Full Text] [Related]
16. Diabetic retinopathy (treatment).
Mohamed QA; Ross A; Chu CJ
BMJ Clin Evid; 2011 May; 2011():. PubMed ID: 21609511
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
[TBL] [Abstract][Full Text] [Related]
18. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
19. Current concepts of pharmacotherapy of diabetic macular edema.
Haritoglou C; Maier M; Neubauer AS; Augustin AJ
Expert Opin Pharmacother; 2020 Mar; 21(4):467-475. PubMed ID: 31957495
[No Abstract] [Full Text] [Related]
20. [Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies].
Lang GE; Lang GK; Deissler HL
Klin Monbl Augenheilkd; 2014 May; 231(5):527-34. PubMed ID: 24799173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
